New funding will power foundational primary cell data generation to advance AI-driven discovery through the company's full product launch.

新资金将用于支持基础原代细胞数据的生成，以推动人工智能驱动的发现，并助力公司完成全线产品发布。

MONTREAL and BOSTON

蒙特利尔和波士顿

,

，

June 22, 2026

2026年6月22日

/PRNewswire/ --

/美通社/ --

DropGenie

DropGenie

, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first product. The round was led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM, and existing investors Real Ventures and Anges Québec continuing their strong support..

，一家致力于推进下一代基因编辑工作流程的生物技术公司，今日宣布完成其Seed+轮融资，以支持其首款产品的发布。本轮融资由Skeleton Key领投，新投资者默克全球健康创新基金（Merck Global Health Innovation Fund）和CQDM参与投资，现有投资者Real Ventures和Anges Québec继续提供强力支持。

This funding will drive commercialization: scaling manufacturing, building commercial operations, and accelerating customer adoption. The rollout follows successful validation through DropGenie's Early Access Program, with many major global pharma, biotech, and research customers already integrating the technology into their workflows..

这笔资金将推动商业化进程：扩大生产规模、构建商业运营体系，并加速客户采用。此次推广是在DropGenie的早期访问计划成功验证之后进行的，许多全球主要的制药、生物技术和研究客户已经将该技术整合到他们的工作流程中。

DropGenie's platform enables high-throughput, miniaturized gene editing workflows that reduce the number of cells and reagents required per experiment — lowering costs and accelerating editing turnaround time. This enables direct edits on primary patient cells, delivering more biologically relevant insights earlier in the R&D process..

DropGenie的平台支持高通量、微型化的基因编辑工作流程，减少每次实验所需的细胞和试剂数量——从而降低成本并加速编辑周转时间。这使得能够直接对患者原代细胞进行编辑，在研发过程的早期阶段提供更具生物学相关性的见解。

'The most powerful insights in biology come from perturbations—changing one thing and watching how a living system responds. But capturing those signals with fidelity demands working at the right scale, in the right cells,' said Alison Hirukawa, CEO & Co-founder of DropGenie. 'Our platform miniaturizes workflows and lowers cell requirements to enable direct editing of primary patient cells—giving researchers access to true biological readouts previously impossible to capture.

“生物学中最深刻的见解来自扰动——改变一个变量并观察生命系统如何响应。但要高保真地捕捉这些信号，就必须在合适的尺度上、在正确的细胞类型中进行操作。”DropGenie 首席执行官兼联合创始人 Alison Hirukawa 表示，“我们的平台将工作流程微型化，并降低了对细胞数量的需求，从而能够直接编辑原代患者细胞，使研究人员能够获得此前无法捕捉的真实生物学读数。”

This opens the door to faster, more predictive development across cell therapy, functional genomics, and beyond.'.

这为细胞治疗、功能基因组学及更广泛领域的更快、更具预测性的开发打开了大门。

'We find the DropGenie platform's ability to reliably miniaturize and accelerate experimental workflows via automation to be extremely compelling,' said Ann Lai, Managing Partner of Skeleton Key. 'Being able to capture every parameter variation of these complex gene editing experimental processes creates the data we need to fundamentally accelerate innovation and to better leverage AI beyond the theoretical discovery phases.

Skeleton Key 的管理合伙人 Ann Lai 表示：“我们发现，DropGenie 平台能够通过自动化可靠地实现实验流程的微型化和加速，这一能力极具吸引力。”“能够捕捉这些复杂基因编辑实验过程中的每一个参数变化，为我们提供了所需的数据，从而从根本上加速创新，并在理论发现阶段之后更好地利用人工智能。”

This is exactly the kind of science technology Skeleton Key wants to support and see succeed.'.

这正是 Skeleton Key 希望支持并见证其成功的科学技术类型。

The Seed+ round powers DropGenie's strategic data partnerships with customers to generate high-quality, standardized gene editing data. As industry demand grows for data infrastructure, DropGenie's efficient process creates foundational datasets that fuel data-driven discovery in cell therapy and functional biology—producing datasets that capture true biology at scale..

Seed+轮融资助力DropGenie与客户建立战略数据合作伙伴关系，以生成高质量、标准化的基因编辑数据。随着行业对数据基础设施的需求不断增长，DropGenie的高效流程构建了基础数据集，为细胞疗法和功能生物学中的数据驱动发现提供动力，从而大规模生成能够真实反映生物学的数据集。

About

关于

DropGenie

DropGenie

DropGenie advances next-generation gene editing through miniaturized, high-efficiency workflows. Based in Montreal and Boston, DropGenie enables direct edits on primary patient cells by dramatically reducing the number of cells required per experiment, delivering true biological signals and accelerating development across cell therapy, functional genomics, and AI-driven discovery.

DropGenie 通过小型化、高效率的工作流程推动下一代基因编辑技术的发展。总部位于蒙特利尔和波士顿的 DropGenie 能够直接在原代患者细胞上进行编辑，大幅减少每次实验所需的细胞数量，提供真实的生物信号，并加速细胞疗法、功能基因组学以及人工智能驱动的药物发现领域的研发进程。

For more information on how we're miniaturizing gene editing workflow, please visit .

如需了解我们如何缩小基因编辑工作流程的更多信息，请访问。

https://dropgenie.com/

https://dropgenie.com/

SOURCE DropGenie

来源：DropGenie

21

二十一

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示